Your Source for Venture Capital and Private Equity Financings

Venture Capital News: 1859 Launches with $40M Series A

2022-02-07
SAN DIEGO, CA, 1859, a platform company to discover new small molecule medicines, launched and announced the close of a Series A funding round of $40 million.
SAN DIEGO, CA, 1859, Inc., a platform company combining artificial intelligence and empirical pico-scale screening data at scale to discover new small molecule medicines for emerging disease targets, launched and announced the close of a highly successful Series A funding round of $40 million led by experienced life science investors Northpond Ventures and OMX Ventures. Existing investors, FusionX Ventures and Vertical Venture Partners also joined the round.

1859 Inc. is a platform company combining artificial intelligence and empirical screening data at scale to discover new small molecule medicines for emerging disease targets. The company partners with pharmaceutical and biotech companies, and academic institutions to dramatically shorten the time and resources needed to identify and screen high-potential compounds for future exploration and development.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors